Comparison of citrate anticoagulation strategies in hemodialysis patients at high risk of bleeding: a prospective observational cohort study.

Shasha Chen, Mingjie Xu, Guisen Li, Daqing Hong

Abstract readObservational StudyComparative Study

In one paragraph

Observational study in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shasha ChenRenal Division and Institute of Nephrology, Sichuan Clinical Research Center for Kidney Disease, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Mingjie XuRenal Division and Institute of Nephrology, Sichuan Clinical Research Center for Kidney Disease, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Guisen LiRenal Division and Institute of Nephrology, Sichuan Clinical Research Center for Kidney Disease, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Daqing HongRenal Division and Institute of Nephrology, Sichuan Clinical Research Center for Kidney Disease, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal regional citrate anticoagulation (RCA) for hemodialysis (HD) in high-bleeding-risk patients remains undefined. This prospective observational cohort study included 195 high-bleeding-risk patients (481 HD sessions) allocated to three RCA groups: RCA-one (prefilter citrate only, 141 patients/337 sessions), RCA-two (pre- and post-filter citrate, 51 patients/133 sessions), and RCA+saline (prefilter citrate + post-filter saline, 3 patients/11 sessions). Primary outcome: circuit survival time; secondary outcomes: complete dialysis rate, clotting scores, and adverse events. RCA-two had the highest complete dialysis rate (99.7% vs. 97.0% [RCA-one], 97.7% [RCA+saline];

Indexed as

AnticoagulantsCitric AcidHemorrhageKidney Failure, ChronicRenal DialysisAgedFemaleHumansMaleMiddle AgedProspective StudiesAnticoagulantsCitric Acidcohort studyHemodialysishigh risk of bleedingregional citrate anticoagulation

Identifiers

PMID41693135

DOI10.1080/0886022X.2026.2624876

PMCPMC12912228

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.